Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00247247
Status:
COMPLETED
Last Update Posted:
2007-06-25
First Post:
2005-10-31
Brief Title:
Comtess Versus Cabaseril as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off
Sponsor:
Orion Corporation Orion Pharma
Organization:
Orion Corporation Orion Pharma
Study Overview
Official Title:
Efficacy and Tolerability of Comtess Versus Cabaseril as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing-Off Phenomenon
Status:
COMPLETED
Status Verified Date:
2007-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multi-centre randomised parallel-group study rater-blinded Total duration of the study per subject is 12 weeks plus a one- to two-week screening period There are 6 pre-planned visits per subject screening visit followed by 5 visits Approximately 300 patients altogether in up to 25 active German study centres and up to 3 active Lithuanian study centres will be randomised
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CAMP | None | None | None |